ethyl (4-nitrobenzyl)phosphinate | 727414-57-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl (4-nitrobenzyl)phosphinate
• CAS: 727414-57-5
• 化学式: C₉H₁₂NO₄P
• 分子量: 229.172
• InChiKey: WMJOQCPOEHIVOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.61
• 重原子数：
  15.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  69.44
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  tri-tert-butyl ester 10-benzyloxymethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid 、 ethyl (4-nitrobenzyl)phosphinate 以 苯 为溶剂， 反应 12.0h， 以85%的产率得到tri-tert-butyl ester 10-[ethoxy-(4-nitrobenzyl)phosphinoylmethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid
  参考文献：
  名称：

  WO2006/45546

  摘要：

  公开号：

文献信息

• Pyridazinone derivatives useful as glucan synthase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2586778A2

  公开（公告）日：2013-05-01

  In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.

  在其许多实施方案中，本发明提供了作为葡聚糖合成酶抑制剂的-取代哒嗪酮化合物、制备此类化合物的方法、包括一种或多种此类化合物的药物、制备包括一种或多种此类化合物或一种或多种此类化合物与其他抗真菌剂的药物制剂的方法，以及使用此类化合物或药物组合物治疗、预防、抑制或改善与葡聚糖合成酶相关的一种或多种真菌感染的方法。
• OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS.
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2499121B1

  公开（公告）日：2015-10-07
• [EN] PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE UTILES EN TANT QU'INHIBITEURS DE SYNTHASE DE GLUCANE
  申请人：SCHERING CORP

  公开号：WO2008115381A1

  公开（公告）日：2008-09-25

  [EN] In its many embodiments, the present invention provides -substituted pyridazinone compounds as glucan synthase inhibitors, methods of preparing such compounds, pharmaceutical including one or more of such compounds, methods of preparing pharmaceutical formulations including one or more such compounds or one or more such compounds along with other antifungal agents, and methods of treatment, prevention, inhibition, or amelioration of one or more fungal infections associated with glucan synthase using such compounds or pharmaceutical compositions.
  [FR] L'invention concerne des composés de pyridazinone substitués en tant qu'inhibiteurs de synthase de glucane ; des procédés de préparation de tels composés, des produits pharmaceutiques comprenant un ou plusieurs de ces composés ; des procédés de préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés seuls ou avec d'autres agents antifongiques ; et des procédés de traitement, de prévention, d'inhibition, ou d'amélioration d'une ou de plusieurs infections fongiques associées à une synthase de glucane utilisant de tels composés ou compositions pharmaceutiques.
• [EN] OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS<br/>[FR] DÉRIVÉS D'OXAZOLINE POUR LE TRAITEMENT DE TROUBLES DU SYSTÈME NERVEUX CENTRAL (CNS)
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011057973A1

  公开（公告）日：2011-05-19

  The invention relates to compounds of formula (I) wherein the definitions of X, R and R1 are provided in claim 1. It has now been found that the compounds of formula (I) have a good affinity to the trace amine associated receptors (TAARs), especially for TAARl. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.